**Description**

**A COMPOSITION FOR THE TREATMENT OF ASTHENIA**

**Technical Field**

The invention relates to a composition formed for the treatment of asthenia.

**State of the Art**

Weakness (also known as asthenia) is the loss of strength in the entire body or in some parts of the body. It is pronounced especially in the adrenal gland diseases and it is also observed in the chronic diseases such as anemia and cancer. Although it may be limited to a certain organ or organ system, some cases show the symptoms affecting the entire body such as respiratory distress, tachycardia, breath shortness, dizziness and sleep withdrawal.

According to the state of the art, the invention no. WO 2001/006873 entitled “Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise” discloses a composition suitable for the prevention and/or treatment of muscular energetic deficiencies and states of asthenia for enhancing sport performances and for the treatment of states of heart fatigue, that may take the form of a dietary supplement, dietetic support or of an actual medicine, which comprises as characterizing active ingredients a combination of L-carnitine and/or at least one alkanoyl L-carnitine and creatinol-phosphate.

Further, the invention no. EP1796702B1 with classification “A61K 36/53” entitled “Use of lavender oil for the prophylaxis and treatment of somatization disorders and posttraumatic stress disorder” relates to the prophylactic and therapeutic use of lavender oil for the treatment of neuro asthenia, somatization disorders and other diseases associated with stress, and the medicaments containing lavender oil and dietary food items, as well as preparations and capsules administered as oral dosage forms.

Further, the invention no. WO 1998/046645 entitled “Method for the production of antihuman antigen receptors and uses thereof” describes a method for the production of an anti-human antigen receptor that is low or not immunogenic in humans comprising the steps of selecting a combination of functionally rearranged VH and VL immunoglobulin chains wherein at least said VH chain is derived from essentially unprimed mature human B-lymphocytes or from essentially anergic human B cells and said VL chain is derived from a naturally occurring human B cell repertoire. Furthermore, receptors that are low or not immunogenic in humans and directed to human antigens are provided, said receptors being obtainable by the method of the invention. Said receptors are preferably antibodies or fragments thereof or immunoconjugates comprising the VH/VL chains of said antibody.

Further, the invention no. EP1358159B1 entitled “3,4-diaminopyridine tartrate and phosphate, pharmaceutical compositions and uses thereof” relates to 3,4-diaminopyridine salts, pharmaceutical compositions containing at least one of said salts and uses thereof for the treatment of botulism, myasthenia, myasthenic syndromes or fatigue.

As a result, the presence of the need for a composition for treating asthenia and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to increase the CYP17A1 expression and support the natural adrenal androgen production.

Another object of the invention is to enable the functions of the adrenal androgens to exhibit rapid action by partial anti-glucocorticoid effect.

Another object of the invention is to suppress the pro-asthenic cytokines such as tnf-alpha and cox-2.

Another object of the invention is to increase the insulin sensitivity and establish an efficient sugar metabolism.

In order to achieve the aforesaid advantages, the invention is a composition for the treatment of asthenia, said composition being obtained by the components selected from the group comprising 3,7-bis(3-trihydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 6-dihydroxyl hecogenin, 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 6-oxo-difluoro-(16,20)-dioscin that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a composition for the treatment of asthenia. Said composition increases the CYP17A1 expression and supports the natural adrenal androgen production, enables the functions of the adrenal androgens to exhibit rapid action by partial anti-glucocorticoid effect, suppresses the pro-asthenic cytokines such as tnf-alpha and cox-2, increases the insulin sensitivity to establish an efficient sugar metabolism.

The composition according to the invention contains 3,7-bis(3-trihydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 6-dihydroxyl hecogenin, 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 6-oxo-difluoro-(16,20)-dioscin.

Said composition is obtained by a mixture of the aforesaid components according to the following ratios by weight:

22-10% 3,7-bis(3-trihydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one,

38-26% 6-dihydroxyl hecogenin,

15-24% 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one,

25-40% 6-oxo-difluoro-(16,20)-dioscin

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for treating asthenia and the manufacture thereof for this purpose.

**CLAIMS**

1. A composition for the treatment of asthenia, said composition being obtained by the components selected from the group comprising 3,7-bis(3-trihydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 6-dihydroxyl hecogenin, 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 6-oxo-difluoro-(16,20)-dioscin that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 22-10% by weight 3,7-bis(3-trihydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one.
3. A composition according to Claim 1 characterized in that it comprises 38-26% by weight 6-dihydroxyl hecogenin.
4. A composition according to Claim 1 characterized in that it comprises 15-24% by weight 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one.
5. A composition according to Claim 1 characterized in that it comprises 25-40% by weight 6-oxo-difluoro-(16,20)-dioscin.
6. Use of the components according to Claims 1 to 5 obtained individually or in combinations from the group consisting of 3,7-bis(3-trihydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one,  6-dihydroxyl hecogenin,   3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 6-oxo-difluoro-(16,20)-dioscin **for the manufacture of a composition for treating asthenia**.

**ABSTRACT**

**A COMPOSITION FOR THE TREATMENT OF ASTHENIA**

The invention relates to a composition formed for the treatment of asthenia.

No figure.